128.20
price down icon0.11%   -0.14
after-market Handel nachbörslich: 128.20
loading
Schlusskurs vom Vortag:
$128.34
Offen:
$128.35
24-Stunden-Volumen:
2.30M
Relative Volume:
0.90
Marktkapitalisierung:
$8.26B
Einnahmen:
$434.41M
Nettoeinkommen (Verlust:
$-128.05M
KGV:
-60.76
EPS:
-2.11
Netto-Cashflow:
$-250.52M
1W Leistung:
-0.04%
1M Leistung:
+0.32%
6M Leistung:
+47.02%
1J Leistung:
+16.17%
1-Tages-Spanne:
Value
$128.20
$128.45
1-Wochen-Bereich:
Value
$128.06
$128.52
52-Wochen-Spanne:
Value
$73.04
$128.52

Blueprint Medicines Corp Stock (BPMC) Company Profile

Name
Firmenname
Blueprint Medicines Corp
Name
Telefon
617-374-7580
Name
Adresse
45 SIDNEY STREET, CAMBRIDGE, MA
Name
Mitarbeiter
649
Name
Twitter
@BlueprintMeds
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
BPMC's Discussions on Twitter

Vergleichen Sie BPMC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BPMC
Blueprint Medicines Corp
128.20 8.26B 434.41M -128.05M -250.52M -2.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-02 Herabstufung Wedbush Outperform → Neutral
2025-03-20 Fortgesetzt Morgan Stanley Equal-Weight
2025-03-18 Eingeleitet Wolfe Research Outperform
2025-03-17 Eingeleitet Jefferies Buy
2025-03-07 Eingeleitet Scotiabank Sector Outperform
2024-11-14 Eingeleitet JP Morgan Overweight
2024-10-24 Eingeleitet UBS Neutral
2024-05-14 Eingeleitet Stephens Overweight
2024-05-06 Hochstufung Leerink Partners Underperform → Market Perform
2023-10-27 Hochstufung Oppenheimer Perform → Outperform
2023-08-21 Bestätigt Needham Buy
2023-07-31 Hochstufung Wells Fargo Equal Weight → Overweight
2023-06-05 Herabstufung SVB Securities Market Perform → Underperform
2023-01-03 Hochstufung Wells Fargo Underweight → Equal Weight
2022-12-14 Eingeleitet Needham Buy
2022-11-02 Herabstufung Oppenheimer Outperform → Perform
2022-09-14 Eingeleitet Berenberg Buy
2022-07-08 Eingeleitet Oppenheimer Outperform
2022-06-27 Eingeleitet Wells Fargo Underweight
2022-06-10 Herabstufung Citigroup Neutral → Sell
2022-06-01 Hochstufung Jefferies Hold → Buy
2022-03-01 Eingeleitet Citigroup Neutral
2022-02-17 Herabstufung SVB Leerink Outperform → Mkt Perform
2022-01-25 Hochstufung Stifel Hold → Buy
2021-11-19 Fortgesetzt Morgan Stanley Equal-Weight
2021-09-30 Fortgesetzt Stifel Hold
2021-06-04 Fortgesetzt Robert W. Baird Outperform
2021-03-31 Eingeleitet Credit Suisse Neutral
2020-12-03 Eingeleitet Stifel Hold
2020-11-02 Bestätigt H.C. Wainwright Buy
2020-11-02 Herabstufung Jefferies Buy → Hold
2020-10-30 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-07-15 Bestätigt H.C. Wainwright Buy
2020-05-05 Eingeleitet Barclays Equal Weight
2020-03-17 Hochstufung BMO Capital Markets Market Perform → Outperform
2020-01-28 Eingeleitet BMO Capital Markets Market Perform
2020-01-27 Eingeleitet BMO Capital Markets Market Perform
2019-11-06 Hochstufung Raymond James Outperform → Strong Buy
2019-10-22 Eingeleitet JMP Securities Mkt Outperform
2019-10-03 Eingeleitet H.C. Wainwright Buy
2019-09-12 Hochstufung Raymond James Mkt Perform → Outperform
2019-08-29 Eingeleitet Piper Jaffray Neutral
2019-08-15 Fortgesetzt Raymond James Mkt Perform
2019-07-18 Eingeleitet Deutsche Bank Buy
2019-05-23 Fortgesetzt Goldman Buy
2019-04-03 Eingeleitet Morgan Stanley Overweight
2018-09-25 Eingeleitet Leerink Partners Outperform
2017-12-11 Bestätigt Goldman Buy
Alle ansehen

Blueprint Medicines Corp Aktie (BPMC) Neueste Nachrichten

pulisher
Jun 17, 2025

Blueprint Medicines (BPMC) Downgraded by Wells Fargo Amid Acquis - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

BPMC: Wells Fargo Downgrades Blueprint Medicines, Lowers Price Target | BPMC Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Sanofi, Blueprint Medicines filed HSR June 9 - MLex

Jun 17, 2025
pulisher
Jun 15, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SVT, SSBK on Behalf of Shareholders - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 14, 2025

Blueprint Medicines’ SWOT analysis: stock poised for growth amid Sanofi acquisition - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

Blueprint Medicines (BPMC) Showcases Groundbreaking Data on Syst - GuruFocus

Jun 13, 2025
pulisher
Jun 12, 2025

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses - PR Newswire

Jun 12, 2025
pulisher
Jun 12, 2025

Blueprint Medicines Stock Experiences Wild Intraday Swing, Closes Flat Amid Strong Momentum - Daily Chhattisgarh News

Jun 12, 2025
pulisher
Jun 11, 2025

Blueprint Medicines stock hits all-time high of $128.3 By Investing.com - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Blueprint Medicines stock hits all-time high of $128.3 - Investing.com

Jun 11, 2025
pulisher
Jun 10, 2025

Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion - MSN

Jun 10, 2025
pulisher
Jun 06, 2025

Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta - Benzinga

Jun 06, 2025
pulisher
Jun 05, 2025

Blueprint Medicines (BPMC): Morgan Stanley Raises Price Target | BPMC Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal - TradingView

Jun 05, 2025
pulisher
Jun 05, 2025

Citigroup Upgrades Blueprint Medicines (BIT:1BPMC) - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

Sanofi to acquire Blueprint Medicines for about $9.1B - Drug Store News

Jun 05, 2025
pulisher
Jun 05, 2025

Blueprint Medicines (BPMC) Target Price Raised by UBS Analyst | - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Blueprint Medicines (BPMC) Target Price Raised by UBS Analyst | BPMC Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Blueprint Medicines (BPMC) Sees Price Target Increase Amid Acquisition News | BPMC Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Sanofi to buy Blueprint Medicines for $9.1B - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

Blueprint Medicines (BPMC) Target Price Increased Following Acqu - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Blueprint Medicines (BPMC) Target Price Increased Following Acquisition News | BPMC Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Stephens & Co. Downgrades Blueprint Medicines (BPMC) to Equal Weight, Cuts PT - Insider Monkey

Jun 05, 2025
pulisher
Jun 05, 2025

Citizens JMP Downgrades Blueprint Medicines (BPMC) to Market Perform - Insider Monkey

Jun 05, 2025
pulisher
Jun 04, 2025

Sanofi to Buy Blueprint for $9.1 Billion Equity Value - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Nasdaq Today Blueprint Medicines Reclassified Kalkine - Kalkine Media

Jun 04, 2025
pulisher
Jun 04, 2025

BPMC Stock Upgraded: Citigroup Raises Price Target Significantly - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

BPMC Stock Upgraded: Citigroup Raises Price Target Significantly | BPMC Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Citi upgrades Blueprint Medicines stock rating after Sanofi acquisition - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Blueprint Medicines (BPMC) Sees Upgrade and Acquisition by Sanof - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Blueprint Medicines Stock Surges as Sanofi Announces $9.5 Billion Acquisition - MSN

Jun 04, 2025
pulisher
Jun 03, 2025

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines CorporationBPMC - Business Wire

Jun 03, 2025
pulisher
Jun 03, 2025

Blueprint Medicines Corporation (BPMC) Downgraded at TD Cowen - Insider Monkey

Jun 03, 2025
pulisher
Jun 03, 2025

Wolfe Research Lowered Blueprint Medicines Corporation (BPMC) from Outperform to Peer Perform - Insider Monkey

Jun 03, 2025
pulisher
Jun 03, 2025

Blueprint Medicines (BPMC) Downgraded Following Acquisition News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Blueprint Medicines (BPMC) Downgraded Following Acquisition News | BPMC Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Blueprint Medicines downgraded to Neutral from Buy at Guggenheim - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Guggenheim Downgrades Blueprint Medicines to Neutral From Buy, Price Target is $132 - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Sanofi to acquire Blueprint for up to $9.5B - Pharma Voice

Jun 03, 2025
pulisher
Jun 03, 2025

Blueprint Medicines (BPMC) Downgraded by JMP Securities | BPMC S - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Blueprint Medicines (BPMC) Downgraded by JMP Securities | BPMC Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Blueprint Medicines (BPMC) Receives Downgrade from Stephens & Co - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Blueprint Medicines (BPMC) Receives Downgrade from Wolfe Research | BPMC Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Wolfe Downgrades Blueprint Medicines to Peer Perform From Outperform - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Blueprint Medicines (BPMC) Downgraded Following Acquisition Deal - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Stephens Downgrades Blueprint Medicines to Equalweight From Overweight, Adjusts PT to $135 From $150 - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

JPMorgan Downgrades Blueprint Medicines to Neutral From Overweight, Adjusts PT to $129 From $130 - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Sanofi to acquire US biotech firm Blueprint for up to $9.5bn - World Pharmaceutical Frontiers

Jun 03, 2025
pulisher
Jun 03, 2025

Blueprint Medicines (BPMC) Downgraded Amid Sanofi Acquisition Pr - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Blueprint Medicines (BPMC) Downgraded Amid Sanofi Acquisition Proposal | BPMC Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Citizens JMP downgrades Blueprint Medicines stock on Sanofi acquisition - Investing.com

Jun 03, 2025

Finanzdaten der Blueprint Medicines Corp-Aktie (BPMC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Blueprint Medicines Corp-Aktie (BPMC) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Albers Jeffrey W.
Director
May 27 '25
Option Exercise
36.05
5,000
180,250
151,630
Albers Jeffrey W.
Director
May 27 '25
Sale
101.14
5,000
505,692
146,630
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):